Printer Friendly

DIANON SYSTEMS INC. ANNOUNCES TECHNOLOGY LICENSING AGREEMENT AND EQUITY INVESTMENT WITH APROGENEX, INC.

 STRATFORD, Conn., June 9 /PRNewswire/ -- DIANON Systems, Inc. (NASDAQ: DIAN) announced today that an agreement has been reached with Aprogenex, Inc. for a strategic alliance in the area of genetic testing. Under the terms of the agreement, DIANON has licensed for a specific term Aprogenex' DNA probe technology designed to identify certain chromosome abnormalities in fetal cells separated from the maternal circulation. Additionally, DIANON will have the right of first refusal for any exclusive license to future genetic technologies developed by Aprogenex.
 The agreement includes a license fee and royalty payments. DIANON will also purchase approximately $700,000 of Aprogenex convertible preferred stock and warrants to purchase additional shares of convertible preferred stock.
 As part of the agreement, Jack Davis, president and Co-CEO of DIANON, will join the Aprogenex board of directors.
 Aprogenex of Houston, Texas, uses proprietary DNA probe technology in the development of medical diagnostic products focused in genetics, oncology, virology and microbiology.
 James B. Amberson, M.D., vice president of marketing at DIANON, noted that, "The technology licensed to DIANON is designed to identify the rare fetal cells circulating in the mother's blood and to analyze those cells for the presence of genetic defects. We believe this technology will offer our customers the promise of major improvements in the accuracy of blood screening for fetal abnormalities as well as avoiding the cost and risk associated with amniocentesis."
 DIANON Systems is a leading provider of innovative testing services and diagnostic information to cancer treating physicians and gynecologists in the United States and Europe.
 -0- 6/9/93
 /CONTACT: Richard A. Sandberg, chairman and co-chief executive officer, 203-381-4022, or John P. Davis, president and co-chief executive officer, 203-381-4033, both of DIANON Systems, Inc./
 (DIAN)


CO: DIANON Systems, Inc.; Aprogenex, Inc. ST: Connecticut IN: MTC SU: LIC

TM -- NY003 -- 6851 06/09/93 08:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 9, 1993
Words:306
Previous Article:RESEARCHERS PRESENT DATA ON PEPTIDES TO IMAGE THROMBUS, ATHEROSCLEROSIS AND INFECTION HERALDING THE NEW WAVE IN NUCLEAR IMAGING AGENTS
Next Article:MICROPROBE INITIATES COUNTERSUIT AGAINST GEN-PROBE
Topics:


Related Articles
APROGENEX INC. FILES REGISTRATION STATEMENT FOR INITIAL PUBLIC OFFERING OF COMMON STOCK
DIANON Systems Reports Fourth Quarter and Year-End Results
DIANON Systems Announces Third Quarter Results.
DIANON Increases Stock Repurchase Program Authorization by $10 Million; The Company Also Withdraws Offer to Acquire UROCOR.
DIANON Systems, Inc. Announces Agreement to Provide Laboratory Services for Oxford Health Plans, Inc.
DIANON Systems, Inc. Signs Letter of Intent to Acquire Assets of Kyto Meridien diagnostics, LLC.
DIANON Systems, Inc. Signs Definitive Agreement to Acquire Assets of Kyto Meridien Diagnostics, LLC.
DIANON Systems Reports Record First Quarter Earnings Results.
DIANON Systems, Inc. Signs Exclusive U.S. Sales and Distribution Agreement with Response Genetics, Inc. for Tumor Specific Gene Expression Analysis.
DIANON Systems Announces National Agreement with UnitedHealthcare.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters